Research Topics
Species | Carlos A ZarateSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
A double-blind, placebo-controlled study of memantine in the treatment of major depressionCarlos A Zarate
Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Human Health Services, Bethesda, MD, USA
Am J Psychiatry 163:153-5. 2006..This study was designed to assess possible antidepressant effects of memantine, a selective N-methyl-D-aspartate (NMDA) receptor antagonist in humans...
Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depressionCarlos A Zarate
Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
Biol Psychiatry 72:331-8. 2012..Ketamine is extensively metabolized. This study examined the relationship between ketamine metabolites and response, diagnosis, and psychotomimetic symptoms in MDD and BD patients...- Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trialCarlos A Zarate
Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, Maryland, USA
Biol Psychiatry 71:939-46. 2012..The present study sought to replicate this finding in an independent sample... - Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot studyCarlos A Zarate
Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
Bipolar Disord 9:561-70. 2007..In this study, we investigated whether antimanic effects can be achieved with a protein kinase C inhibitor in subjects with mania... - The role of AMPA receptor modulation in the treatment of neuropsychiatric diseasesCarlos A Zarate
Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health/NIH, 10 Center Drive, Bethesda, MD 20892, USA
Exp Neurol 211:7-10. 2008 - An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depressionCarlos A Zarate
Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland, USA
Biol Psychiatry 57:430-2. 2005..This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in bipolar depression... - Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorderCarlos A Zarate
Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, Bethesda, Maryland, USA
Biol Psychiatry 59:1006-20. 2006.... - Glutamatergic modulators: the future of treating mood disorders?Carlos Zarate
Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
Harv Rev Psychiatry 18:293-303. 2010..Overall, this system holds considerable promise for developing the next generation of novel therapeutics for the treatment of bipolar disorder and major depressive disorder... - A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depressionCarlos A Zarate
Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, Bethesda, MD 20892, USA
Arch Gen Psychiatry 63:856-64. 2006..Converging lines of evidence suggest the role of the glutamatergic system in the pathophysiology and treatment of mood disorders... - Riluzole in psychiatry: a systematic review of the literatureCarlos A Zarate
Mark O Hatfield CRC, Bethesda, Maryland 20892, USA
Expert Opin Drug Metab Toxicol 4:1223-34. 2008..Riluzole, a neuroprotective agent with anticonvulsant properties approved for the treatment of amyotrophic lateral sclerosis (ALS) is one such agent... - Protein kinase C inhibitors: rationale for use and potential in the treatment of bipolar disorderCarlos A Zarate
Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Bethesda, Maryland, USA
CNS Drugs 23:569-82. 2009..The development of CNS-penetrant PKC inhibitors may have considerable benefit for this devastating illness... - Pramipexole for bipolar II depression: a placebo-controlled proof of concept studyCarlos A Zarate
Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institute of Health, Department of Human and Health Services, Bethesda, Maryland, USA
Biol Psychiatry 56:54-60. 2004..02). One subject on pramipexole and two on placebo developed hypomanic symptoms. CONCLUSIONS: The dopamine agonist pramipexole was found to have significant antidepressant effects in patients with bipolar II depression... - Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic systemCarlos A Zarate
Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, Maryland 20892, USA
Ann N Y Acad Sci 1003:273-91. 2003.... - Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonistRodrigo Machado-Vieira
Mood and Anxiety Disorders Program, Laboratory of Molecular Psychiatry and Experimental Therapeutics, National Institute of Mental Health NIMH, National Institutes of Health NIH, Department of Health and Human Services, Bethesda, Maryland, USA
J Clin Psychiatry 70:1662-6. 2009..This study investigated whether changes in brain-derived neurotrophic factor (BDNF) levels are associated with the initial antidepressant effects of ketamine, a high-affinity N-methyl-D-aspartate (NMDA) antagonist... - Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamineGiacomo Salvadore
Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
Neuropsychopharmacology 35:1415-22. 2010..73, p=0.0021, FDR <0.05).These data implicate the pgACC and its putative interaction with the amygdala in predicting antidepressant response to ketamine in a working memory task context... - A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depressionNancy Diazgranados
Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
Arch Gen Psychiatry 67:793-802. 2010..Pharmacological strategies that produce rapid antidepressant effects-for instance, within a few hours or days-would have an enormous impact on patient care and public health... - Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depressionDavid A Luckenbaugh
Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Program, Department of Health and Human Services, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
Bipolar Disord 14:880-7. 2012..This study investigated whether FHP influences ketamine's antidepressant and perceptual effects in individuals with bipolar depression... - Habenula volume in bipolar disorder and major depressive disorder: a high-resolution magnetic resonance imaging studyJonathan B Savitz
Mood and Anxiety Disorders Program, National Institutes of Health National Institute of Mental Health, Bethesda, Maryland, USA
Biol Psychiatry 69:336-43. 2011..We conducted the first magnetic resonance imaging analysis of habenula volume in MDD and bipolar disorder (BD)... - Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depressionBrian R Cornwell
Section on Neurobiology of Fear and Anxiety, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA
Biol Psychiatry 72:555-61. 2012..Acutely, ketamine increases extracellular glutamate levels, neuronal excitability, and spontaneous γ oscillations, but it is unknown whether these effects are key to the mechanism of antidepressant action of ketamine... - Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled studyLobna Ibrahim
Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Programs, National Institute of Mental Health NIMH, National Institutes of Health NIH, Bethesda, MD, USA
Neuropsychopharmacology 37:1526-33. 2012.... - A comparison of cognitive functioning in medicated and unmedicated subjects with bipolar depressionM Kathleen Holmes
Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
Bipolar Disord 10:806-15. 2008..The present study aims to compare the cognitive performance of medicated and unmedicated subjects with bipolar depression to healthy control subjects... - Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorderNancy Diazgranados
National Institute of Mental Health, and Department of Human Health Services, Bethesda, Maryland, USA
J Clin Psychiatry 71:1605-11. 2010..We examined the effects of a single dose of ketamine on suicidal ideation in subjects with treatment-resistant major depressive disorder (MDD)... - An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depressionGiacomo Salvadore
Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
Int J Neuropsychopharmacol 15:1063-72. 2012.... - Abnormal hippocampal functioning and impaired spatial navigation in depressed individuals: evidence from whole-head magnetoencephalographyBrian R Cornwell
Mood and Anxiety Disorders Program, NIMH, 15K North Dr, MSC 2670, Bethesda, MD 20892, USA
Am J Psychiatry 167:836-44. 2010..The authors aimed to link spatial navigation deficits previously documented in depressed patients to abnormal hippocampal functioning using a virtual reality navigation task... - Early intervention in bipolar disorder, part II: therapeuticsGiacomo Salvadore
Mood and Anxiety Disorders Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
Early Interv Psychiatry 2:136-46. 2008..We also discuss their potential use as early intervention strategies for improving symptoms and functioning in patients in the earliest stages of BPD, as well as high-risk individuals... - Ketamine and the next generation of antidepressants with a rapid onset of actionRodrigo Machado-Vieira
Experimental Therapeutics Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Health and Human Services, Bethesda, Maryland, USA
Pharmacol Ther 123:143-50. 2009..Overall, understanding the molecular basis of this work will likely lead to the ultimate development of improved therapeutics for MDD... - Regional cerebral glucose metabolic abnormalities in bipolar II depressionLinda Mah
Section on Neuroimaging in Mood and Anxiety Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA
Biol Psychiatry 61:765-75. 2007..This study investigated whether cerebral metabolic abnormalities previously reported in unmedicated BD subjects are evident in depressed bipolar disorder type II (BD II) subjects receiving lithium or divalproex... - A developmental study of the neural circuitry mediating motor inhibition in bipolar disorderJudah D Weathers
Section on Bipolar Spectrum Disorders, Emotion and Development Branch, NIMH, Bethesda, MD, USA
Am J Psychiatry 169:633-41. 2012..The authors compared the neural circuitry mediating this process in bipolar youths relative to bipolar adults and in healthy volunteers... - An open-label trial of riluzole in patients with treatment-resistant major depressionCarlos A Zarate
Laboratory of Molecular Pathophysiology and Experimental Therapeutics and the Pathophysiology Branch, Mood and Anxiety Disorders Program, NIMH, Department of Health and Human Services, NIH, Bethesda, MD 20892, USA
Am J Psychiatry 161:171-4. 2004..This study was conducted to determine the efficacy and safety of riluzole, a glutamate-modulating agent, in patients with recurrent major depression... - Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonistLaura E Phelps
Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health DHHS, 10 Center Drive, Bethesda, MD 20892 1282, USA
Biol Psychiatry 65:181-4. 2009..This study investigated whether a family history of alcohol dependence influences ketamine's initial antidepressant effect... - Bcl-2 polymorphism influences gray matter volume in the ventral striatum in healthy humansGiacomo Salvadore
Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Health and Human Services, Bethesda, Maryland 20892, USA
Biol Psychiatry 66:804-7. 2009..We tested the hypothesis that this SNP would modulate gray matter (GM) volume in the limbic-cortical-striatal-pallidal-thalamic circuitry that plays major roles in mood regulation... - Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptorsSungho Maeng
Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
Biol Psychiatry 63:349-52. 2008..Understanding the mechanisms underlying the intriguing effects of N-methyl d-aspartate (NMDA) antagonists could lead to novel treatments with a rapid onset of action... - A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorderNancy Diazgranados
Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, 10 Center Drive, CRC, Unit 7 Southeast, Room 7 3445, Bethesda, MD 20892, USA
Curr Psychiatry Rep 10:510-9. 2008..We conclude that PKC is an important target-arguably the first mechanistically distinct drug target for bipolar disorder. PKC holds considerable promise as a novel target for developing a new line of treatments for bipolar disorder... - Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depressionLobna Ibrahim
Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, CRC Unit 7 Southeast, Room 7 3445, Bethesda, MD 20892, USA
Prog Neuropsychopharmacol Biol Psychiatry 35:1155-9. 2011..However, it remains unknown whether ketamine is equally effective in patients with MDD who previously also did not respond to electroconvulsive therapy (ECT)... - The neurobiology of the switch process in bipolar disorder: a reviewGiacomo Salvadore
Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, Maryland, USA
J Clin Psychiatry 71:1488-501. 2010..In this review, we summarize the clinical evidence regarding somatic interventions associated with switching, with a particular focus on the biologic underpinnings presumably involved in the switch process... - A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorderLobna Ibrahim
Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
J Clin Psychopharmacol 32:551-7. 2012..Further studies with larger sample sizes are necessary to confirm these preliminary findings... - Population-based input function and image-derived input function for [¹¹C](R)-rolipram PET imaging: methodology, validation and application to the study of major depressive disorderPaolo Zanotti-Fregonara
Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
Neuroimage 63:1532-41. 2012.... - Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): a pilot studyLobna Ibrahim
Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, United States
Brain Res Bull 86:129-33. 2011..These results suggest that SD is associated with mood-related changes in plasma VEGF levels, but not plasma BDNF levels. Further studies using larger sample sizes are needed to confirm these preliminary findings... - Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targetsPaul J Carlson
Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland 20892, USA
NeuroRx 3:22-41. 2006.... - Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depressionHusseini K Manji
Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland 20892-4405, USA
Biol Psychiatry 53:707-42. 2003..The development of novel, nonaminergic-based therapeutics holds much promise for improved treatment of severe, refractory mood disorders... - The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesisRodrigo Machado-Vieira
Experimental Therapeutics, Mood and Anxiety Disorders Research Program, NIMH NIH, Department of Health and Human Services, Bethesda, MD 20892, USA
Bipolar Disord 11:92-109. 2009..Continued work to decipher lithium's molecular actions will likely lead to the development of not only improved therapeutics for BD, but to neurotrophic enhancers that could prove useful in the treatment of many other illnesses... - Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamineGiacomo Salvadore
Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
Biol Psychiatry 65:289-95. 2009..We also investigated patterns of ACC activity to rapid presentation of fearful faces compared with the normal habituation observed in healthy subjects... - Perception of facial emotion in adults with bipolar or unipolar depression and controlsKathryn L Schaefer
Department of Counseling and Personnel Services, University of Maryland, College Park, MD, USA
J Psychiatr Res 44:1229-35. 2010..Groups were compared in terms of sensitivity and accuracy in identifying emotions. Our preliminary findings suggest that subjects with bipolar depression may have emotional processing abnormalities relative to controls... - Performance on a virtual reality spatial memory navigation task in depressed patientsNeda F Gould
Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, NIMH, Mark O Hatfield Clinical Research Center, 10 Center Dr, Bethesda, MD 20892, USA
Am J Psychiatry 164:516-9. 2007..Findings on spatial memory in depression have been inconsistent. A navigation task based on virtual reality may provide a more sensitive and consistent measure of the hippocampal-related spatial memory deficits associated with depression... - Targeting glutamatergic signaling for the development of novel therapeutics for mood disordersRodrigo Machado-Vieira
Experimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health NIH, 10 Center Drive, Bethesda, MD 20892, USA
Curr Pharm Des 15:1595-611. 2009..This paper reviews the currently available knowledge regarding the role of the glutamatergic system in the etiopathogenesis of mood disorders and putative glutamate modulators... - The Bcl-2 gene polymorphism rs956572AA increases inositol 1,4,5-trisphosphate receptor-mediated endoplasmic reticulum calcium release in subjects with bipolar disorderRodrigo Machado-Vieira
Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, Maryland, USA
Biol Psychiatry 69:344-52. 2011..Here, we examined the effects of the Bcl-2 gene single nucleotide polymorphism (SNP) rs956572 on intracellular Ca(2+) dynamics in patients with BPD... 
Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorderMaura L Furey
Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA
JAMA Psychiatry 70:280-90. 2013..Scopolamine produces rapid antidepressant effects and thus offers the opportunity to characterize potential biomarkers of treatment response within short periods...- Acute D-serine treatment produces antidepressant-like effects in rodentsOz Malkesman
Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
Int J Neuropsychopharmacol 15:1135-48. 2012..It is unclear whether D-serine has a convergent influence on downstream synaptic plasticity cascades that may yield a similar therapeutic profile to NMDA antagonists like ketamine... - Baseline mood-state measures as predictors of antidepressant response to scopolamineMaura L Furey
Experimental Therapeutics and Pathophysiology Branch, NIMH, NIH, Bethesda, MD 20892, USA
Psychiatry Res 196:62-7. 2012..These results indicate that self-report mood-ratings obtained before treatment can predict response outcome to scopolamine, and suggest that a constellation of mood-state features may be related to clinical response... - Prefrontal cortical abnormalities in currently depressed versus currently remitted patients with major depressive disorderGiacomo Salvadore
Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
Neuroimage 54:2643-51. 2011..Consistent with other neuroimaging and post-mortem neuropathological studies of MDD, we also found evidence of decreased white matter in patients with dMDD and rMDD... - The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disordersRodrigo Machado-Vieira
Experimental Therapeutics, Mood and Anxiety Disorders Research Program, NIMH NIH, Bethesda, Maryland 20892, USA
Neuroscientist 15:525-39. 2009..In therapeutically relevant paradigms, ketamine preferentially targets postsynaptic AMPA/NMDA receptors, and riluzole preferentially targets presynaptic voltage-operated channels and glia... - Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episodeGiacomo Salvadore
Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, CRC Unit 7 Southeast, Room 7 3445, Bethesda, Maryland, 20892 1285, USA
Prog Neuropsychopharmacol Biol Psychiatry 34:819-21. 2010..Overall, our findings suggest a novel mechanism in the pathophysiology of BPD... - Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorderRodrigo Machado-Vieira
Mood and Anxiety Disorders Program, National Institute of Mental Health, Department of Health and Human Services, Bethesda, MD 20892 1282, USA
J Clin Psychiatry 69:946-58. 2008..This article reviews the published data related to different aspects of rapid improvement of depressive symptoms... - New therapeutic targets for mood disordersRodrigo Machado-Vieira
Experimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
ScientificWorldJournal 10:713-26. 2010.... - The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disordersJing Du
Laboratory of Molecular Pathophysiology, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
Neuropsychopharmacology 32:793-802. 2007.... - Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactionsRodrigo Machado-Vieira
Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, and Department of Health and Human Services, Bethesda, MD 20892, USA
CNS Neurosci Ther 17:699-704. 2011.... - Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorderKristine Erickson
Mood and Anxiety Disorders Program, National Institute of Mental Health, MD 20814 9692, USA
Am J Psychiatry 162:2171-3. 2005..This study investigated performance of unmedicated depressed patients on the Affective Go/No-Go Task... - Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorderWallace C Duncan
Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
Int J Neuropsychopharmacol 16:301-11. 2013..Further studies are required to confirm the link found here between behavioural and synaptic changes, as well as to test the reliability of these central and peripheral biomarkers of rapid antidepressant response... - Early improvement with lithium in classic mania and its association with later responseRodrigo Machado-Vieira
Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, NIH, Bethesda, MD, USA
J Affect Disord 144:160-4. 2013..This study investigated whether early improvement (within one week) to lithium monotherapy predicted later response and remission in individuals with BD mania... - Effects of lithium on oxidative stress parameters in healthy subjectsRushaniya Khairova
Experimental Therapeutics, Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
Mol Med Rep 5:680-2. 2012..Overall, the present findings indicate a potential role for the antioxidant effects of lithium in healthy subjects, supporting its neuroprotective profile in bipolar disorder (BD) and, possibly, in neurodegenerative processes... - Glycogen synthase kinase-3: a target for novel bipolar disorder treatmentsTodd D Gould
Laboratory of Molecular Pathophysiology, National Institute of Mental Health, NIH, Bethesda, MD 20892, USA
J Clin Psychiatry 65:10-21. 2004..We conclude with a discussion of the GSK-3 inhibitors furthest in development and the clinical trials that may emerge... - Early intervention in bipolar disorder, part I: clinical and imaging findingsGiacomo Salvadore
Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892, USA
Early Interv Psychiatry 2:122-35. 2008..A companion paper discusses the cellular and molecular mechanisms of action of agents with neurotrophic and neuroplastic properties, with a particular emphasis on lithium and valproate... - Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to dateDaniel C Mathews
Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
Drugs 72:1313-33. 2012..There is extant evidence that the glutamatergic system holds considerable promise for developing the next generation of novel and mechanistically distinct agents for the treatment of MDD... - Differing amygdala responses to facial expressions in children and adults with bipolar disorderPilyoung Kim
NIMH, Bethesda, MD, USA
Am J Psychiatry 169:642-9. 2012..The authors used functional MRI to compare amygdala activity during a face processing task in children and adults with bipolar disorder and in healthy comparison subjects... - Combination treatment in bipolar disorder: a review of controlled trialsCarlos A Zarate
The Mood and Anxiety Disorders Program, National Institute of Mental Health, Bethesda, MD 20892, USA
Bipolar Disord 5:217-25. 2003..This article reviews the available published data from controlled, blinded studies regarding combination treatments in the different treatment phases of bipolar disorder... - Bipolar disorder: candidate drug targetsCarlos A Zarate
Laboratory of Molecular Pathophysiology and Experimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, Bethesda, MD, USA
Mt Sinai J Med 75:226-47. 2008..Intracellular pathways and targets worthy of further study include glycogen synthase kinase-3 protein, protein kinase C, and the arachidonic acid cascade... - Pharmacological treatment of psychiatric comorbidity in bipolar disorder: a review of controlled trialsJaskaran B Singh
Mood and Anxiety Disorders Research Program, National Institute of Mental Health, 10 Center Drive, Bethesda, MD 20892, USA
Bipolar Disord 8:696-709. 2006..CONCLUSIONS: Treatment of psychiatric comorbidities in bipolar disorder is not based on controlled data but is largely empirically based. Controlled trials in patients with bipolar disorder and comorbidity are urgently needed... - Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patientsCarlos A Zarate
Consolidated Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Mass, USA
Am J Psychiatry 161:169-71. 2004..The goal of this study was to determine the benefits of the continued use of a typical antipsychotic agent following remission from an acute manic episode... - Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depressionXiaochen Zhao
Department of Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, NY, USA
Br J Clin Pharmacol 74:304-14. 2012.... - Timing is everything: does the robust upregulation of noradrenergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation?Jennifer L Payne
Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, Maryland 20892 1283, USA
Biol Psychiatry 52:921-6. 2002.... - A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trialSanjay J Mathew
Mood and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
Eur Neuropsychopharmacol 21:221-9. 2011..The selective NK(1)R antagonist GR205171 had fewer adverse effects but was not significantly superior to placebo in the short-term treatment of chronic PTSD. (ClinicalTrials.gov Identifier: NCT 00211861, NCT 00383786)... - Identification of molecular mechanisms underlying mood stabilization through genome-wide gene expression profilingRulun Zhou
Laboratory of Molecular Pathophysiology, National Institute of Mental Health, Bethesda, MD 20892-3711, USA
Int J Neuropsychopharmacol 9:263-6. 2006 - Cortical abnormalities in bipolar disorder investigated with MRI and voxel-based morphometryAllison C Nugent
Section on Neuroimaging in Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, 1 Center Drive, MSC 0135, Bethesda, MD 20892 0135, USA
Neuroimage 30:485-97. 2006.... - Neurobiology of bipolar disorderAndrew R Newberg
National Institute of Mental Health, 10 Center Drive, MSC 1282, Building 10 CRC, Room 7 5545, Bethesda, MD 20892 1282, USA
Expert Rev Neurother 8:93-110. 2008.... - Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week studyMauricio Tohen
Lilly Research Laboratories, IN 46285, USA
Am J Psychiatry 160:1263-71. 2003..Few double-blind trials have compared longer-term efficacy and safety of medications for bipolar disorder. The authors report a 47-week comparison of olanzapine and divalproex... - A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar maniaRodrigo Machado-Vieira
Bipolar Disorder Research Program, Espirita Hospital of Porto Alegre, Porto Alegre, RS, Brazil
J Clin Psychiatry 69:1237-45. 2008..This study aimed to evaluate the efficacy and tolerability of the purinergic agents allopurinol and dipyridamole combined with lithium in bipolar mania... - The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrenceMauricio Tohen
Lilly Research Laboratories, Brougher Building, 525 South Meridian, Indianapolis, IN 46225, USA
Am J Psychiatry 160:2099-107. 2003..Since improved prediction of illness course early in bipolar disorder is required to guide treatment planning, the authors evaluated recovery, first recurrence, and new illness onset following first hospitalization for mania... - Olanzapine versus divalproex in the treatment of acute maniaMauricio Tohen
Lilly Research Laboratories, Indianapolis, IN 46285, USA
Am J Psychiatry 159:1011-7. 2002..The effects of olanzapine and divalproex for the treatment of mania were compared in a large randomized clinical trial... - Targeting the glutamatergic system to develop novel, improved therapeutics for mood disordersGerard Sanacora
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06510, USA
Nat Rev Drug Discov 7:426-37. 2008..We also discuss exciting new prospects for the development of improved therapeutics for these devastating disorders... - Olanzapine versus placebo in acute mania: treatment responses in subgroupsRoss J Baldessarini
International Consortium for Bipolar Disorder Research, Department of Psychiatry and Neuroscience Program, Harvard Medical School, Boston, MA, USA
J Clin Psychopharmacol 23:370-6. 2003..5-1.7, all P < 0.01). These well-powered comparisons of subgroups of interest indicate broad efficacy of olanzapine in the treatment of acute mania... - The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effectsSungho Maeng
Curr Psychiatry Rep 9:467-74. 2007.... - Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigineJaskaran Singh
Psychopharmacology (Berl) 173:227-8. 2004 - Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapyMauricio Tohen
Lilly Research Laboratories, Eli Lilly and Co, Indianapolis, IN 46285, USA
Arch Gen Psychiatry 59:62-9. 2002..CONCLUSION: Compared with the use of valproate or lithium alone, the addition of olanzapine provided superior efficacy in the treatment of manic and mixed bipolar episodes... - A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depressionSusan L McElroy
Psychopharmacology Research Program, University of Cincinnati College of Medicine, 231 Bethesda Avenue, Cincinnati, OH 45267 0559, USA
J Clin Psychiatry 65:204-10. 2004..Lamotrigine has demonstrated efficacy for the acute treatment of depression in bipolar I patients in a placebo-controlled, monotherapy study. We describe the results of a 52-week, open-label continuation of that trial... - Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trialRoy H Perlis
Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
J Clin Psychiatry 67:1747-53. 2006..To compare olanzapine and risperidone in the treatment of nonpsychotic acute manic or mixed episodes... - Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser aloneMauricio Tohen
Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
Br J Psychiatry 184:337-45. 2004..Aims To evaluate whether olanzapine plus either lithium or valproate reduces the rate of relapse, compared with lithium or valproate alone... - Increased rate of non-right-handedness in patients with bipolar disorderCecylia Nowakowska
J Clin Psychiatry 69:866-7. 2008 - Overweight and obesity in bipolar disordersPo W Wang
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Room 2117, CA 94305-5723, USA
J Psychiatr Res 40:762-4. 2006